Umbilical Cord Blood Cell Isolation via Sedimentation and Magnetic Beads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and expanding hematopoietic stem cells, natural killer cells, and T cells are limited by cell count, purification, and availability issues, as well as complications such as graft-versus-host disease, HLA matching, viral transmission, and affordability, which restrict their therapeutic use.
Innovation Solution
A method involving sedimentation with hydroxyethyl starch, gelatin, and chitosan to obtain leucocyte rich plasma, followed by red blood cell lysis using ammonium chloride and cord/maternal plasma proteins, and immunomagnetic bead separation to enrich CD34+, CD133+, CD38-, CD56+, and CD3+ cells, achieving high purity and viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used for isolating and expanding hematopoietic stem cells, natural killer cells, and T cells, then cell isolation can be achieved, but cell count, purification, and availability are limited
Solution Approach 1:
The patent divides the cell isolation process into multiple sequential steps: (1) sedimentation to separate leucocytes from red blood cells, (2) immunomagnetic bead separation to isolate specific cell populations (HSCs, NK cells, T cells) from the leucocyte fraction. This segmentation allows each step to optimize for its specific function, achieving both high purification and adequate cell counts
Solution Approach 2:
The patent uses immunomagnetic beads coated with specific antibodies (anti-CD34 for HSCs, anti-CD56 for NK cells, anti-CD3 for T cells) as intermediaries to selectively bind and separate target cells. These beads act as mediators that enable specific cell population isolation while maintaining cell viability and function
2Reliability
If hematopoietic stem cell transplantation is performed, then therapeutic potential is achieved, but complications such as graft-versus-host disease, HLA matching requirements, and viral transmission risks occur
Solution Approach 1:
The patent extracts and isolates specific cell populations (HSCs, NK cells, T cells) from umbilical cord blood with high purity through sedimentation and immunomagnetic separation. This extraction of pure cell populations reduces contamination from unwanted cell types that could contribute to graft-versus-host disease, while maintaining therapeutic efficacy
Solution Approach 2:
The patent utilizes the presence of umbilical cord blood as a source, which naturally contains high levels of immunomodulatory factors and cytokines that promote engraftment and reduce graft-versus-host disease risk. The method converts the potential harm of using non-matched donors into a benefit by leveraging the immunoprotective properties of cord blood-derived cells
3Ease of manufacture
If extensive clinical research and conventional methods are used, then various cell isolation techniques are available, but affordability and availability are restricted
Solution Approach 1:
The patent employs a universal isolation protocol using sedimentation reagents and immunomagnetic beads that can isolate multiple cell types (HSCs, NK cells, T cells) from a single umbilical cord blood sample. This multi-functional approach simplifies the overall process by combining multiple isolation functions into a unified method, reducing complexity while improving availability
Solution Approach 2:
The patent uses commercially available immunomagnetic bead kits and standard sedimentation reagents that are relatively inexpensive and single-use. This approach eliminates the need for complex, expensive, and specialized equipment while achieving high-purity cell isolation, making the method more affordable and widely accessible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables efficient isolation and expansion of enriched hematopoietic stem cells, natural killer cells, and T cells with high purity and viability, reducing the risk of graft-versus-host disease and viral transmission, while providing a more accessible and cost-effective source for therapeutic applications.
Implementation Method 1
separating leucocytes from umbilical cord blood using a sedimentation reagent to obtain leucocyte rich plasma
Implementation Method 2
adding red blood cell lysis buffer to the leucocyte rich plasma to obtain leucocyte concentrate
Implementation Method 3
incubating the leucocyte concentrate with CD34+, CD133+ and CD38− immunomagnetic beads for obtaining hematopoietic stem cells
Data Source
AI summary
The present disclosure discloses pharmaceutical compositions comprising hematopoietic stem cells (HSC) cells, NK cells, and T cells individually, having positive and negative surface markers and pharmaceutically acceptable excipients. The present disclosure further relates to the method for preparing the composition thereof. The present disclosure also provides a method of treating a subject comprising the use of any of said compositions in treating diseases selected from the group consisting of graft versus host disease, malignant disease, and non-malignant disease.